Vaginal Estrogen vs Systemic HRT: Which One Do You Actually Need?

What Is the Core Difference Between Vaginal Estrogen and Systemic HRT?

Vaginal estrogen acts locally. Systemic HRT acts everywhere. That one sentence captures the clinical divide that guides prescribing decisions for perimenopausal and postmenopausal women. Vaginal estrogen restores the epithelial thickness, glycogen content, and acidic pH of vulvovaginal tissue without raising serum hormone levels in a clinically meaningful way. Systemic HRT raises circulating estrogen enough to suppress vasomotor symptoms, protect bone density, and support mood, cardiovascular function, and cognitive health.

Genitourinary syndrome of menopause (GSM) is the current term replacing the older "vulvovaginal atrophy." It includes vaginal dryness, burning, irritation, dyspareunia, urinary urgency, recurrent urinary tract infections, and reduced lubrication during arousal. The North American Menopause Society (NAMS) 2023 position statement on hormone therapy states that "for women whose primary complaint is genitourinary, vaginal estrogen therapy is preferred over systemic estrogen" because local treatment resolves GSM symptoms with a fraction of the systemic dose [1].

Systemic HRT, by contrast, is indicated when vasomotor symptoms (hot flashes, night sweats), sleep disruption, mood instability, sexual dysfunction beyond GSM, or osteoporosis prevention are the primary concerns. The 2022 Menopause Society guidelines rate systemic estrogen-progestogen therapy as the most effective available intervention for moderate-to-severe vasomotor symptoms [2].

A 12-week randomized trial published in Menopause (N=209) found that low-dose vaginal estradiol cream significantly improved vaginal maturation index scores and reduced dyspareunia, while serum estradiol remained below 20 pg/mL throughout the study [3].

How Vaginal Estrogen Works: Formulations, Doses, and Expected Results

Vaginal estrogen is available in four delivery formats, each with different dosing schedules and tissue-contact profiles.

Creams. Estradiol 0.01% cream (Estrace Vaginal) is applied with an applicator. A typical starting dose is 2 to 4 g nightly for two weeks, then 1 g one to three times weekly for maintenance. Conjugated estrogens cream (Premarin Vaginal, 0.625 mg/g) follows a similar schedule. Creams allow flexible dosing and can be applied externally to the vulva, which matters when the introitus and outer tissue are also symptomatic.

Tablets and inserts. The 10 mcg estradiol vaginal insert (Vagifem, Yuvafem) is placed with a single-use applicator nightly for two weeks, then twice weekly. Serum estradiol in one pharmacokinetic study peaked at 35 pg/mL on day one of treatment and fell to baseline levels (below 10 pg/mL) within two weeks of twice-weekly dosing [4]. This is the formulation most often cited as safe for breast cancer survivors when systemic therapy is contraindicated.

Ring. Estring releases approximately 7.5 mcg of estradiol per 24 hours over 90 days. It is replaced every three months and produces the lowest systemic absorption of any vaginal estrogen product [5].

Gel. Estradiol 0.003% vaginal gel (Intrarosa is prasterone, not estradiol gel, see below) is not yet widely available in the United States. In Canada and parts of Europe, estradiol 0.005% vaginal gel is prescribed off-label for GSM.

The NAMS 2023 guidelines state explicitly that "low-dose vaginal estrogen products are not associated with an increased risk of endometrial hyperplasia, and routine endometrial surveillance is not required" [1]. This removes one of the biggest hesitations clinicians and patients have about local therapy.

Published data from the REVIVE survey (N=3,046 women with GSM) showed that 73% of women reported vaginal dryness as bothersome, 62% reported pain during sex, and fewer than 25% had discussed treatment options with a physician [6]. Awareness of local estrogen options remains low despite the evidence base.

How Systemic HRT Works: Routes, Doses, and What It Treats

Systemic HRT raises circulating estradiol to levels similar to the early follicular phase of a premenopausal cycle, typically 40, 100 pg/mL depending on dose and route.

Oral estradiol. Standard doses range from 0.5 mg to 2 mg daily. First-pass hepatic metabolism raises SHBG, C-reactive protein, and triglyceride levels modestly compared to transdermal routes [7].

Transdermal estradiol. Patches (Vivelle-Dot, Climara), gels (Divigel, EstroGel), and sprays (Evamist) bypass hepatic first-pass metabolism. The ESTHER study (N=881) found that transdermal estradiol was not associated with increased venous thromboembolism risk, while oral estradiol carried an odds ratio of 4.0 for VTE compared to non-users [8]. This is why transdermal delivery is now preferred for women with cardiovascular risk factors.

Progestogen requirement. Any woman with an intact uterus who takes systemic estrogen must take a progestogen to prevent endometrial hyperplasia and cancer. Options include micronized progesterone (Prometrium 200 mg for 12 days per cycle or 100 mg daily continuous), medroxyprogesterone acetate (MPA), norethindrone acetate, and the levonorgestrel intrauterine system. The PEPI trial demonstrated that unopposed estrogen produced endometrial hyperplasia in 62% of women over three years versus 2% in the placebo group [9].

What systemic HRT does not reliably fix. Even at therapeutic serum levels, systemic estrogen may not fully restore vaginal tissue. A study in Obstetrics and Gynecology (N=158) found that 32% of women on systemic HRT still met diagnostic criteria for GSM based on vaginal pH above 5.0 and maturation index findings [10]. This is why adding vaginal estrogen to systemic HRT is a recognized prescribing strategy rather than a redundant one.

The NAMS 2022 hormone therapy position statement notes that "women experiencing persistent vaginal symptoms despite systemic therapy should be offered concurrent low-dose vaginal estrogen" [2].

Can You Use Both Vaginal Estrogen and Systemic HRT at the Same Time?

Yes, and a meaningful proportion of women require both. The clinical scenario is common: a woman on transdermal estradiol for hot flashes and sleep disruption still reports vaginal dryness and pain during sex. Adding vaginal estrogen in this setting is supported by evidence and endorsed by NAMS, ACOG, and the British Menopause Society [1, 2, 11].

Safety data support the combination. A retrospective cohort study published in JAMA Internal Medicine (N=45,663 postmenopausal women) found no significant increase in breast cancer risk with low-dose vaginal estrogen used alone or in combination with systemic therapy over a median follow-up of 9.6 years [12]. The authors noted that serum estradiol levels in the vaginal-estrogen-only group remained within the expected postmenopausal range throughout the observation period.

When prescribing both, clinicians should document the indication for each, confirm that the uterus is present or absent (for progestogen planning), and schedule a follow-up at three months to assess vaginal and systemic symptom response separately.

A practical prescribing framework: assess symptoms in two separate columns. Column one lists systemic symptoms (hot flashes, insomnia, mood, bone risk). Column two lists local symptoms (dryness, dyspareunia, recurrent UTI, urinary urgency). If column one is empty and column two is not, vaginal estrogen alone is appropriate. If both columns have items, systemic HRT plus vaginal estrogen is likely needed. If only column one has items, systemic HRT alone is the starting point, with reassessment of column two at three months.

Prasterone vs Vaginal Estradiol: A Direct Comparison

Prasterone (brand name Intrarosa) is the only non-estrogen vaginal insert approved by the FDA for dyspareunia due to GSM. It is dehydroepiandrosterone (DHEA) delivered as a 6.5 mg daily vaginal insert. Local vaginal cells convert DHEA into both estrogens and androgens through intracrine metabolism. Because conversion happens inside the cell, serum estradiol and testosterone remain at or below postmenopausal baseline levels during treatment [13].

This is the central clinical advantage of prasterone for women who cannot or prefer not to use any estrogen, even locally. The FDA approval was based on the SYNFLORIX-comparable ERC-230 and ERC-231 phase III trials, which collectively enrolled 557 women. At 12 weeks, prasterone produced statistically significant improvements in vaginal dryness, dyspareunia, and maturation index versus placebo (P<0.001) [13].

Vaginal estradiol at 10 mcg twice weekly has been studied more extensively across longer durations and demonstrates comparable tissue-level benefits in head-to-head pilot data. A 2020 review in Menopause concluded that prasterone and vaginal estradiol produced similar improvements in vaginal pH and maturation index at 12 weeks, though direct randomized comparisons remain limited [14].

Key differences to know:

• Prasterone is dosed daily (no loading/maintenance phase split). Vaginal estradiol inserts are daily for two weeks, then twice weekly.
• Prasterone produces local androgen effects that may improve clitoral sensitivity and sexual desire beyond what estrogen alone delivers.
• Vaginal estradiol has a longer safety record (decades vs. less than 10 years post-approval for prasterone) and lower per-dose cost in most formularies.
• Both are classified by ACOG as acceptable for breast cancer survivors in consultation with their oncologist [11].

Ospemifene (Osphena 60 mg oral daily) is a third non-vaginal option: a selective estrogen receptor modulator that acts as an estrogen agonist in vaginal tissue and an antagonist in breast tissue. It is FDA-approved for moderate-to-severe dyspareunia and vaginal dryness due to GSM [15]. It does carry a black-box warning about endometrial effects with long-term use and is contraindicated in women with a history of VTE.

Addyi vs Vyleesi: Treating Hypoactive Sexual Desire Disorder

Neither vaginal estrogen nor systemic HRT directly targets hypoactive sexual desire disorder (HSDD), a diagnosis distinct from GSM. HSDD is characterized by persistently low sexual desire causing personal distress, and it requires its own treatment pathway.

Two FDA-approved medications exist for premenopausal HSDD.

Flibanserin (Addyi) was approved by the FDA in August 2015 at a dose of 100 mg taken orally at bedtime. Its mechanism is central: it acts as a 5-HT1A agonist and 5-HT2A antagonist, modulating dopaminergic and noradrenergic pathways in the prefrontal cortex. The VIOLET trial (N=1,090) found that flibanserin increased satisfying sexual events by approximately 0.5 to 1.0 additional events per month vs. placebo over 24 weeks, with a statistically significant reduction in distress scores [16]. It carries a black-box warning for hypotension and syncope when combined with alcohol or CYP3A4 inhibitors. It is approved for premenopausal women only.

Bremelanotide (Vyleesi) was approved by the FDA in June 2019 as a 1.75 mg subcutaneous auto-injector used at least 45 minutes before anticipated sexual activity, no more than once in 24 hours and eight times per month. Its mechanism is melanocortin receptor agonism (MC4R) in the central nervous system. The RECONNECT trials (two key studies, combined N=1,247 premenopausal women with HSDD) found bremelanotide produced a statistically significant decrease in distress (P<0.001) and an increase in desire scores compared to placebo at 24 weeks [17]. Common adverse effects include transient nausea (40% of users), flushing, and blood pressure elevation lasting approximately 12 hours per dose.

How Addyi and Vyleesi differ practically:

Addyi requires nightly dosing regardless of sexual activity, and full effect takes four to eight weeks to emerge. Vyleesi is on-demand, which suits women whose desire fluctuates situationally. Nausea with Vyleesi is more pronounced but time-limited. Neither drug is appropriate for women with cardiovascular disease, uncontrolled hypertension, or active liver disease. Neither is a substitute for vaginal estrogen in women with concurrent GSM, and the two drug classes can be prescribed together when both HSDD and GSM are present.

For postmenopausal women with HSDD, neither drug is FDA-approved, though off-label use of both occurs. Systemic testosterone (off-label in the United States; approved in Australia and parts of Europe as Intrinsa) has a stronger evidence base for HSDD in postmenopausal women. A meta-analysis in The Lancet Diabetes and Endocrinology (N=8 trials, 3,035 women) found that testosterone therapy significantly increased satisfying sexual events, desire, arousal, and orgasm scores versus placebo, with no significant increase in adverse cardiometabolic events over trial durations of 12 to 24 weeks [18].

Safety, Cancer Risk, and Who Should Avoid Each Option

The safety conversation around HRT changed significantly after the Women's Health Initiative (WHI) initial publications in 2002 and 2004 generated widespread alarm about breast cancer and cardiovascular risk. Subsequent re-analyses have substantially revised that picture.

The WHI estrogen-plus-MPA arm (N=16,608) found a hazard ratio of 1.26 for invasive breast cancer after a mean 5.6 years of use [19]. The estrogen-only arm (N=10,739, hysterectomized women) found a hazard ratio of 0.79, meaning estrogen alone was associated with a reduced breast cancer risk over 7.2 years of follow-up [19]. The difference matters: MPA, not estrogen, appears to drive most of the breast cancer signal in combined HRT. This has shifted prescribing toward micronized progesterone over MPA for women with a uterus, though definitive randomized data comparing the two progestogens on breast cancer outcomes are still limited.

For vaginal estrogen specifically, the absolute risk data are reassuring. The Danish study cited earlier (N=45,663) found no statistically significant breast cancer risk with low-dose vaginal estrogen used continuously for up to 10 years [12]. The FDA prescribing information for 10 mcg vaginal estradiol inserts acknowledges this low-risk profile while maintaining a class warning for estrogen products.

Women who should discuss options carefully with a clinician before starting any estrogen include those with a personal history of estrogen-receptor-positive breast cancer, active or recent VTE, undiagnosed uterine bleeding, active liver disease, or known or suspected pregnancy. For most breast cancer survivors, ACOG Practice Bulletin 141 states that vaginal estrogen at low doses "may be appropriate after consultation with the oncologist, particularly when non-hormonal therapies have failed" [11].

Non-hormonal alternatives for GSM include vaginal moisturizers (polycarbophil-based, used three times weekly), lubricants for intercourse, and ospemifene. Non-hormonal alternatives for vasomotor symptoms include escitalopram 10 to 20 mg daily, venlafaxine 37.5 to 75 mg daily, and fezolinetant (Veozah 45 mg daily), an FDA-approved neurokinin 3 receptor antagonist approved in May 2023 specifically for vasomotor symptoms [20].

Monitoring, Follow-Up, and When to Reassess

Starting any estrogen or hormonal treatment creates a monitoring obligation. For vaginal estrogen alone, a follow-up at 8 to 12 weeks to assess symptom response, vaginal tissue appearance, and any unexpected bleeding is standard. Ongoing endometrial surveillance by ultrasound is not required for low-dose vaginal estrogen per the NAMS 2023 guidelines unless uterine bleeding occurs [1].

For systemic HRT, annual review should include blood pressure measurement, breast exam, a symptom inventory reassessing both systemic and local symptoms, and updated cardiovascular risk assessment. The NAMS and ACOG both recommend that the decision to continue HRT be revisited annually and that "there is no mandatory stopping age for hormone therapy in healthy women" if the benefit-risk balance remains favorable [2, 11].

Women taking flibanserin should be counseled to avoid alcohol entirely and to report any dizziness or syncopal episodes. Women using bremelanotide should be advised about the nausea timeline and blood pressure changes, and should have baseline blood pressure confirmed below 160/100 mmHg before the first dose per FDA labeling [17].

Testosterone off-label use for HSDD in postmenopausal women requires monitoring of serum total testosterone at baseline and at three months, with a target of maintaining levels in the physiologic premenopausal range (15 to 70 ng/dL) per the Global Consensus Position Statement on testosterone in women, published jointly in The Journal of Clinical Endocrinology and Metabolism in 2019 [21].